Unlabelled: The critical study showing advantages of intensive insulin therapy in comparison with the classic method was Diabetes Control and Complications Trial. Conclusion of that study was unequivocal: hyperglycemia has a significant influence on the development of the chronic diabetes complications. THE AIM of this study was to estimate the influence of the conventional insulin therapy in the past and its duration on the development of complications in patients suffering from type 1 diabetes for more than 5 years.
Material And Methods: 185 patients aged 16.7 years (+/-3.4) with diabetes onset in the age 8.4 years (+/-3.8) participated in this study. There were 84 girls and 101 boys. More of them were treated by classic insulin therapy at the beginning of disease (n=148). 37 persons had intensive insulin therapy all the time.
Results: The presence of at least one complication was found in 49 persons (26.5%), two complications - in 14 patients (7.57%) and three complications in 4 patients (2.16%). The conventional therapy duration was twice longer in patients with retinopathy. The significant influence of the age, the age of diabetes onset and duration was found in those patients. Comparing the groups of patients treated conventionally less than 3.5 years and more than 3.5 years it was found that patients in the first group were older, fell ill later and they had longer diabetes duration than patients in the second group. The risk of retinopathy increases from 4.2% to 8.9% in patients treated conventionally more than 3.5 years. The risk of diabetic cataract is 5 times higher in that group.
Conclusions: Chronic complications of diabetes occur in 26.5 % patients with a diabetes duration of at least 5 years. CIT is the risk factor of the eye complications in diabetes, particularly when applied longer than 3.5 years. The prolongation of CIT over 3.5 years increases the risk of retinopathy twice and the risk of cataract 5 times in patients with type 1 diabetes. So the early intensification of insulin therapy reduces the risk of the retinopathy and cataract development in later course of the disease.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Role of HbA1c in Mortality Among Patients With a Medical History of Ischemic Stroke and Paroxysmal Atrial Fibrillation: A Systematic Review.
Cureus
December 2024
Medicine, Jinnah Hospital, Lahore, Lahore, PAK.
Elevated HbA1c, a marker of poor glycemic control, is associated with adverse cardiovascular outcomes and mortality. HbA1c influences outcomes through distinct mechanisms of vascular dysfunction and atherosclerosis in ischemic stroke, during atrial remodeling and thrombus formation in paroxysmal atrial fibrillation (PAF). Optimal HbA1c thresholds are generally below optimal levels, with levels above this being linked to higher mortality in both populations.
View Article and Find Full Text PDFCase Report: Efficacy and safety of recombinant growth hormone therapy in a girl with Loeys-Dietz syndrome.
Front Cardiovasc Med
January 2025
Department of Pediatric Endocrinology and Rheumatology, Institute of Pediatrics, Poznan University of Medical Sciences, Poznan, Poland.
Background: Loeys-Dietz syndrome (LDS) is a clinically and genetically heterogeneous, autosomal dominant aortic aneurysm syndrome with widespread systemic involvement. We present the case of a 16.5-year-old girl with LDS type 2 (LDS2) caused by a heterozygous pathogenic variant, c.
View Article and Find Full Text PDFThe regulation of PKC epsilon (PKCepsilon) and its downstream effects is still not fully understood, making it challenging to develop targeted therapies or interventions. A more precise tool that enables spatiotemporal control of PKCepsilon activity is thus required. Here, we describe a photo-activatable optogenetic PKCepsilon probe (Opto-PKCepsilon) consisting of an engineered PKCepsilon catalytic domain and a blue-light inducible dimerization domain.
View Article and Find Full Text PDFInsulin Titration Recommendations When Using Glucagon-Like Peptide 1 Receptor Agonist Therapy in Adults With Type 1 Diabetes.
Clin Diabetes
September 2024
Division of Endocrinology, Diabetes and Metabolism, Indiana University School of Medicine, Indianapolis, IN.
Safety and effectiveness in an uncontrolled setting of glucagon-like-peptide-1 receptor agonists in patients with familial partial lipodystrophy: Real-life experience from a national reference network.
Diabetes Obes Metab
January 2025
Endocrinology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Paris, France.
Aim: To describe the effects of Glucagon-like peptide-1 receptor agonists (GLP-1RA) in patients with familial partial lipodystrophy (FPLD) assessed in a real-life setting in a national reference network.
Patients And Methods: We retrospectively collected clinical and metabolic parameters in patients with FPLD in the French lipodystrophy reference network, who initiated GLP-1RA. Data were recorded before, at one-year (12 ± 6 months) and at the latest follow-up on GLP-1RA therapy (≥18 months).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!